Finasteride/tamsulosin - GL PharmTech

Drug Profile

Finasteride/tamsulosin - GL PharmTech

Alternative Names: GL2701; Tamsulosin/finasteride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GL PharmTech
  • Class Androstenes; Antiandrogens; Antineoplastics; Azasteroids; Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia(In volunteers) in South Korea (PO, Capsule)
  • 12 Mar 2014 GL PharmTech announces intention to submit NDA in 2017
  • 29 Feb 2012 The Korea University Anam Hospital & GL PharmTech complete a phase I trial in Healthy volunteers in South Korea (NCT01829893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top